


09/785,805 04-13-06
DOCKET NO.: ALZA-0141R

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In Re Application of:

Quittard, *et al.*

Patent No.: 6,919,092 B2 ✓

Issue Date: July 19, 2005

For: METHOD FOR THE MANAGEMENT OF INCONTINENCE

Confirmation No.: 4150

Group Art Unit: 1616

Examiner: Evelyn Huang

EXPRESS MAIL LABEL NO.: EV 765640625 US
DATE OF DEPOSIT: April 12, 2006

EV765640625US

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

☒ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☒ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

☒ Copies of reference numbers **365** to **368** listed on the attached Form PTO-1449 are enclosed herewith.


☒ Copies of reference numbers **369** to **384** on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2).

☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

There are no listed references which are not in the English language.


Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: April 12, 2006


Wendy A. Choi
Registration No. 36,697

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2006 WW



DOC NO.: ALZA-0141R

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Guittard, *et al.*

Confirmation No.: 4150

Patent No.: 6,919,092 B2

Group Art Unit: 1616

Issue Date: July 19, 2005

Examiner: Evelyn Huang

For: METHOD FOR THE MANAGEMENT OF INCONTINENCE

EXPRESS MAIL LABEL NO: EV 765640625 US
DATE OF DEPOSIT: April 12, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

CERTIFICATION UNDER 37 CFR § 1.97(e)

In accordance with 37 CFR § 1.97(e), certification is hereby made that:

- ☐ Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.
- ☒ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

Date: April 12, 2006


Wendy A. Choi
Registration No. 36,697

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ALZA-0141R	Patent No. 6,919,092 B2
	Applicant Guittard, et al.	
	Issued Date July 19, 2005	Group 1616
	Confirmation No. 4150	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

365	In the United States Court of Appeals for the Federal Circuit, Alza Corporation, Plaintiff, v. Mylan Laboratories, Inc. and Mylan Pharmaceuticals, Inc., Defendants, Alza Corporation v. Impax Laboratories, Inc., Defendant, Brief for Plaintiff-Appellant, January 17, 2006 , 1-69
366	In the United States Court of Appeals for the Federal Circuit, Alza Corporation, Plaintiff, v. Mylan Laboratories, Inc. and Mylan Pharmaceuticals, Inc., Defendants, Alza Corporation v. Impax Laboratories, Inc., Defendant, Brief for Defendant-Appellee (IMPAX Laboratories, Inc.), March 8, 2006 , 1-32
367	In the United States Court of Appeals for the Federal Circuit, Alza Corporation, Plaintiff, v. Mylan Laboratories, Inc. and Mylan Pharmaceuticals, Inc., Defendants, Alza Corporation v. Impax Laboratories, Inc., Defendant, Brief for Defendant-Appellee (Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc.), March 8, 2006 , 1-65 and JA 20000-20088
368	In the United States Court of Appeals for the Federal Circuit, Alza Corporation, Plaintiff, v. Mylan Laboratories, Inc. and Mylan Pharmaceuticals, Inc., Defendants, Alza Corporation v. Impax Laboratories, Inc., Defendant, Reply Brief for Plaintiff-Appellant, April 3, 2006 , 1-32

EXAMINER	DATE CONSIDERED
-----------------	------------------------



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ALZA-0141	Patent No. 6,919,092 B2
	Applicant Guittard, et al.	
	Issued Date July 19, 2005	Group 1616
	Confirmation No. 4150	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	369	5,945,123	08/31/99	Hermelin	424	464
	370	6,031,003	02/29/00	Nemeth, <i>et al.</i>	514	579
	371	6,056,968	05/02/00	Gilbert, <i>et al.</i>	424	422
	372	5,091,189	02/25/92	Heafield, <i>et al.</i>	424	457
	373	5,874,107	02/23/99	Fischer, <i>et al.</i>	424	464
	374	6,075,044	06/13/00	Wang, <i>et al.</i>	514	415
	375	6,129,930	10/10/00	Bova	424	468
	376	5,492,917	02/20/96	Rivero, <i>et al.</i>	514	319
	377	6,110,499	08/29/00	Shivanand, <i>et al.</i>	514	473
	378	5,506,270	04/09/96	Upton, <i>et al.</i>	514	730
	379	6,071,970	06/06/00	Mueller, <i>et al.</i>	514	648
	380	6,096,339	08/01/00	Ayer, <i>et al.</i>	424	473
	381	5,591,452	01/07/97	Miller, <i>et al.</i>	514	468
	382	6,093,420	07/25/00	Baichwal	424	468
	383	6,024,981	02/15/00	Khankari, <i>et al.</i>	424	464
	384	6,068,859	05/30/00	Curatolo, <i>et al.</i>	424	490
EXAMINER				DATE CONSIDERED		